Lantheus doses first patient in SPARROW Phase 2/3 prostate cancer imaging trial
The registrational study of LNTH-2401 is designed to generate data for a future diagnostic performance readout.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Lantheus Holdings, Inc. (LNTH) Doses First Patient in SPARROW Phase 2/3 Registrational Trial
Lantheus dosed the first patient in SPARROW, a Phase 2/3 registrational trial of GRPR-targeted PET agent LNTH-2401 in prostate cancer, with Phase 3 planned to enroll ~400 participants and assess sensitivity and specificity vs histopathology.Material DetailsContext by AI AnalystThis is an early-to-m…